<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886574</url>
  </required_header>
  <id_info>
    <org_study_id>HY-2009-11</org_study_id>
    <nct_id>NCT00886574</nct_id>
  </id_info>
  <brief_title>Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events</brief_title>
  <acronym>CAPPA</acronym>
  <official_title>Multi-Center, Randomized, Open Label Study of the Efficacy of Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events With Korean Type 2 DM Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hanyang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, randomized controlled study aims to evaluate the efficacy of Cilostazol
      versus Aspirin for primary prevention of atherosclerotic events with Korean type 2 Diabetes
      Mellitus (DM) patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal and mean intima media thickness (IMT) of both common carotid artery of the cilostazol group in comparison with the aspirin group</measure>
    <time_frame>every 6 months following randomization, for 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Events of the ischemic heart disease</measure>
    <time_frame>every 12 months following randomization, for 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events of cerebrovascular disease</measure>
    <time_frame>every 12 months following randomization, for 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events of peripheral vascular disease</measure>
    <time_frame>every 12 months following randomization, for 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events of hemorrhagic vascular complication</measure>
    <time_frame>every 12 months following randomization, for 48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 100 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cilostazol 200 mg (50 mg 2T twice per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Cilostazol 200 mg (50 mg 2T twice per day)</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>Pletaal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>100 mg once a day</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes mellitus with high risk of macrovascular complications; high risk is
             one or more as follows:

               -  Hypertension (â‰§ 140/90 or anti-hypertensive therapy)

               -  Hypercholesterolemia (LDL-C &gt; 130 mg/dL or anti-hyperlipidemic therapy)

               -  TG &gt; 200 mg/dL

               -  Non proliferative retinopathy or macular edema

               -  Microalbuminuria or macroalbuminuria

               -  Smoker

          2. Patients on no anti PLT drug history

          3. Patients who are agree with this research

        Exclusion Criteria:

          1. Type 1 diabetes mellitus

          2. Macrovascular complication history

          3. Uncontrolled hypertension, unstable angina history

          4. Congestive heart failure

          5. Bleeding tendency

          6. Chronic liver disease (ALT &gt; 100 or AST &gt; 100) or Chronic renal disease creatinine &gt;
             3.0 mg/dl)

          7. Anemia (hemoglobin &lt; 10 mg/dl) or thrombocytopenia (platelet count less than
             100,000/mm3)

          8. Pregnant or lactation women

          9. Plan to be revascularized in 4 weeks

         10. Plan to go to surgery or invasive intervention in 4 weeks

         11. Plan to need to admission for acute cardiovascular disease in 4 weeks

         12. Contraindication of this medication

         13. Other anti-PLT drug therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongsoo Park, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Hanyang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>In Cheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Hospital</name>
      <address>
        <city>Pyungcheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung hee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>June 3, 2010</last_update_submitted>
  <last_update_submitted_qc>June 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yongsoo, Park, M. D.</name_title>
    <organization>Department of Internal Medicine, Hanyang University</organization>
  </responsible_party>
  <keyword>Cilostazol versus Aspirin</keyword>
  <keyword>Anti-PLT drug</keyword>
  <keyword>Primary Prevention of Atherosclerotic Events</keyword>
  <keyword>Type 2 DM</keyword>
  <keyword>Intima media thickness (IMT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

